Serum BCMA Biomarker

What is BCMA?

BCMA (B-cell maturation antigen) is present on normal and malignant B-cells that play a key role in immune function.

  • The binding of APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor, also known as BLyS) to the membrane bound form of BCMA stimulates normal and malignant B-cell proliferation and antibody production.1

What is Serum BCMA?

Serum B-cell maturation antigen (sBCMA): a novel biomarker to predict outcomes for multiple myeloma (MM) patients.

  • The membrane bound BCMA can be cleaved by gamma secretase, resulting in its release into the blood as sBCMA.2
  • sBCMA is found at low levels in the serum of normal patients and elevated among patients with MM.3
  • Baseline sBCMA levels predict patient outcomes.
  • Changes in sBCMA levels have been found to correlate with a MM patient’s clinical status in response to treatment.4, 5

Serum BCMA is:

  • Elevated in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia (WM).
  • Reduced among those with reduced amounts of B-­cells (immune deficiency syndromes).
Read More

What is Serum BCMA?

Serum B-cell maturation antigen (sBCMA): a novel biomarker to predict outcomes for multiple myeloma (MM) patients.

  • The membrane bound BCMA can be cleaved by gamma secretase, resulting in its release into the blood as sBCMA.2
  • sBCMA is found at low levels in the serum of normal patients and elevated among patients with MM.3
  • Baseline sBCMA levels predict patient outcomes.
  • Changes in sBCMA levels have been found to correlate with a MM patient’s clinical status in response to treatment.4, 5

Serum BCMA is:

  • Elevated in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia (WM).
  • Reduced among those with reduced amounts of B-­cells (immune deficiency syndromes).
Read More

What is the Serum BCMA Test?

The sBCMA test is a simple blood test to determine serum levels of the BCMA protein and is being developed to track MM and CLL.*

  • sBCMA is measured using an enzyme-linked immunosorbent assays (ELISA).6
  • The sBCMA test is performed weekly during the first month of any new treatment and then monthly thereafter.
  • sBCMA levels are elevated with increases in severity of disease and decrease with response to therapy.7
*The sBCMA test has not yet been cleared for clinical diagnostics use in any regulatory jurisdiction. For Research Use Only.

For Healthcare Providers

For Patients and Caregivers

sBCMA testing & services

Serum BCMA Test Attributes

Being developed for improved monitoring of treatment response in MM and will be the first serum biomarker for CLL.*

  • Prognostic, predictive and  monitoring applications in a single test.
  • Predicts outcomes including  progression-­free survival and overall survival.
  • Potential to determine risk of conversion:
    • Pre-myeloma (monoclonal gammopathy of unknown significance) to active MM.
    •  Smoldering MM to active MM.
    •  ‘Watch and wait’ CLL to requiring drug therapy.
  • Uniquely applicable for monitoring of non and oligo-secretory MM.
  • Results are independent of renal function.
*The sBCMA test has not yet been cleared for clinical diagnostics use in any regulatory jurisdiction. For Research Use Only.
Learn More
References:

  1. Thompson, Jeffrey S.; Schneider, Pascal; Kalled, Susan L.; Wang, LiChun; Lefevre, Eric A.; Cachero, Teresa G.; MacKay, Fabienne; Bixler, Sarah A.; Zafari, Mohammad; Liu, Zhong-Ying; Woodcock, Stephen A. (2000-07-03). “Baff Binds to the Tumor Necrosis Factor Receptor–Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population”. Journal of Experimental Medicine. 192 (1): 129–136. doi:10.1084/jem.192.1.129. ISSN 0022-1007. PMC 1887706. PMID 10880534.
  2. Laurent, Sarah A.; Hoffmann, Franziska S.; Kuhn, Peer-Hendrik; Cheng, Qingyu; Chu, Yuanyuan; Schmidt-Supprian, Marc; Hauck, Stefanie M.; Schuh, Elisabeth; Krumbholz, Markus; Rübsamen, Heike; Wanngren, Johanna (2015-06-11). “γ-secretase directly sheds the survival receptor BCMA from plasma cells”. Nature Communications. 6 (1): 7333. Bibcode:2015NatCo…6.7333L. doi:10.1038/ncomms8333. ISSN 2041-1723. PMC 4490565. PMID 26065893.
  3. Pj, Maglione; Hm, Ko; M, Tokuyama; G, Gyimesi; C, Soof; M, Li; E, Sanchez; H, Chen; L, Radigan (2020). “Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies”. The journal of allergy and clinical immunology. In practice. National Center for Biotechnology Information. PMID 31430592. Retrieved 2020-05-30.
  4. ^ Sanchez, Eric; Li, Mingjie; Kitto, Alex; Li, Jennifer; Wang, Cathy S.; Kirk, Dylan T.; Yellin, Ori; Nichols, Cydney M.; Dreyer, Marissa P.; Ahles, Cameryn P.; Robinson, Austin (2012). “Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival”. British Journal of Haematology. 158 (6): 727–738. doi:10.1111/j.1365-2141.2012.09241.x. PMID 22804669.
  5. ^ Ghermezi, Michael; Li, Mingjie; Vardanyan, Suzie; Harutyunyan, Nika Manik; Gottlieb, Jillian; Berenson, Ariana; Spektor, Tanya M.; Andreu-Vieyra, Claudia; Petraki, Sophia; Sanchez, Eric; Udd, Kyle (2017). “Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients”. Haematologica. 102 (4): 785–795. doi:10.3324/haematol.2016.150896. ISSN 0390-6078. PMC 5395119. PMID 28034989.
  6. Sanchez, Eric; Smith, Emily J.; Yashar, Moryel A.; Patil, Saurabh; Li, Mingjie; Porter, Autumn L.; Tanenbaum, Edward J.; Schlossberg, Remy E.; Soof, Camilia M.; Hekmati, Tara; Tang, George (2018). “The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma”. Targeted Oncology. 13 (1): 39–47. doi:10.1007/s11523-017-0538-x. ISSN 1776-2596. PMID 29230672.
  7. ^ Ghermezi, Michael; Li, Mingjie; Vardanyan, Suzie; Harutyunyan, Nika Manik; Gottlieb, Jillian; Berenson, Ariana; Spektor, Tanya M.; Andreu-Vieyra, Claudia; Petraki, Sophia; Sanchez, Eric; Udd, Kyle (2017). “Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients”. Haematologica. 102 (4): 785–795. doi:10.3324/haematol.2016.150896. ISSN 0390-6078. PMC 5395119. PMID 28034989.

How can we help you?